Insights
Investor Narrative

Too Many True Things: Why Biotech Investor Stories Lose Their Hierarchy

When every valid claim receives equal weight, the central investment thesis becomes harder to identify.

When every true claim carries equal weight, an investor has to rank them for you, on twenty minutes of attention and less context than anyone in the room. Decide the thesis first, in one sentence, then sort every other claim into what carries it and what answers a question nobody has asked yet.

The pattern

A company has been working for six years. The platform is real, the lead program has data, the second program is differentiated, the team has run this play before, the market is large, the regulatory path is known, and the manufacturing is solved.

Every one of those statements is true. Every one of them appears in the deck, on the website and in the data room, at roughly the same size, in roughly the same tone, with roughly the same amount of supporting detail.

That is the failure. Not one weak claim among strong ones. Eight strong claims, and no instruction about which one the company is actually asking to be funded on.

Why it breaks

Hierarchy is not a design decision that gets applied at the end. It is an argument, and someone has to make it.

Inside the company nobody wants to make it, because every claim belongs to somebody. The platform belongs to the founding science. The second program belongs to the person who fought for it. The manufacturing story belongs to the operations lead who solved a genuinely hard problem. Ranking the claims means telling six senior people that their contribution is supporting detail this quarter.

So the ranking is quietly deferred, and the materials are built as a union of what everyone contributed. The deck grows. The website grows a section. The scientific figure grows a fourth panel.

An investor reading that has to do the ranking themselves, on twenty minutes of attention, with less context than anyone in the room. They will do it badly, and they will do it in a direction the company did not choose.

What changes

Decide the thesis first, in words, before anything is designed.

One sentence that states what the company is asking to be believed. Then rank every other claim by how directly it supports that sentence. Three tiers is usually enough: the thesis, the claims that carry it, and the detail that answers a question the audience has not asked yet.

The third tier does not get deleted. It gets moved. It belongs in the appendix, the data room, the second conversation, the science page rather than the homepage. Detail placed where it answers a question is worth more than the same detail placed where it competes with the thesis.

The practical result

The changes show up as omissions, and they are visible immediately.

The first screen of the website says one thing. The first four slides make one argument. The scientific figure has a focal point and everything else in it is deliberately quieter. The pipeline table stops implying that eight programs are equally close.

And the material gets shorter, not because brevity was the objective, but because a claim that has been ranked third no longer needs to fight for space in the first two minutes.

An investor who understands what the company leads with can then evaluate it. That is the whole point: hierarchy is not simplification, it is the difference between an argument and an inventory.

Read Insights Explore the Work